# Dapagliflozin

## Forxiga 10mg

##### 

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | OFOR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Indications        | Chronic kidney disease， (At risk of progression) to reduce the risk of sustained estimated GFR decline， end-stage kidney disease， cardiovascular death， and hospitalization for heart failureView additional information. Disorder of cardiovascular system; Prophylaxis - Type 2 diabetes mellitusView additional information. Heart failure， (NYHA class II to IV， reduced ejection fraction) to reduce risk of cardiovascular death and hospitalizationView additional information. Type 2 diabetes mellitus. |
| Dosing             | Type 2 diabetes initial 5 mg once daily， max 10 mg/day.Heart failure 10 mg once daily.                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Contraindications  | Dialysis. Serious hypersensitivity reaction (eg， anaphylactic reaction or angioedema) to dapagliflozin. Renal impairment estimated GFR less than 30 mL/min/1.73 m(2) in type 2 diabetes.                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Common Renal: Urinary tract infectious disease (4.3% to 5.7% ) Reproductive: Female genital infection (6.9% to 8.4% ) Respiratory: Nasopharyngitis (6.3% to 6.6% ) Serious Cardiovascular: Hypotension Endocrine metabolic: Diabetic ketoacidosis (0.3% )， Hypoglycemia Immunologic: Hypersensitivity reaction (Severe) (0.3% ) Renal: Acute injury of kidney， Pyelonephritis， Sepsis due to urinary tract infection Reproductive: Fournier's gangrene， Genital infection (4.8% to 5.7% )                          |
| Pregnancy          | No (limited) human data – animal data suggest low risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

